These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18393914)

  • 1. Statins for the prevention of first or recurrent stroke.
    Athyros VG; Kakafika AI; Tziomalos K; Papageorgiou AA; Karagiannis A
    Curr Vasc Pharmacol; 2008 Apr; 6(2):124-33. PubMed ID: 18393914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin: its clinical role in cerebrovascular prevention.
    Gaspardone A; Arca M
    Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin therapy for stroke prevention.
    Nassief A; Marsh JD
    Stroke; 2008 Mar; 39(3):1042-8. PubMed ID: 18258828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins and stroke prevention.
    Paciaroni M; Hennerici M; Agnelli G; Bogousslavsky J
    Cerebrovasc Dis; 2007; 24(2-3):170-82. PubMed ID: 17596685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins and stroke.
    Leys D; Deplanque D
    Therapie; 2003; 58(1):49-58. PubMed ID: 12822200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Callahan A; Amarenco P; Goldstein LB; Sillesen H; Messig M; Samsa GP; Altafullah I; Ledbetter LY; MacLeod MJ; Scott R; Hennerici M; Zivin JA; Welch KM;
    Arch Neurol; 2011 Oct; 68(10):1245-51. PubMed ID: 21670382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient.
    Ong HT
    QJM; 2005 Aug; 98(8):599-614. PubMed ID: 16006501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stroke prevention, blood cholesterol and statins.
    Amarenco P; Lavallée PC; Labreuche J; Touboul PJ
    Acta Neurol Taiwan; 2005 Sep; 14(3):96-112. PubMed ID: 16252611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Statins in the secondary prevention of stroke: New evidence from the SPARCL Study].
    Castilla-Guerra L; Fernández-Moreno Mdel C; López-Chozas JM
    Clin Investig Arterioscler; 2016; 28(4):202-8. PubMed ID: 26150172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Secondary prevention of recurrent stroke by lowering cholesterol levels and blood pressure].
    Stalenhoef AF
    Ned Tijdschr Geneeskd; 2006 Sep; 150(39):2127-30. PubMed ID: 17059084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Statins and prevention of strokes].
    Neau JP; Moumy H; Mathis S; Gil R
    Rev Neurol (Paris); 2005 Feb; 161(2):237-44. PubMed ID: 15798527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials: Evidence and unanswered questions--hyperlipidaemia.
    Deanfield JE
    Cerebrovasc Dis; 2003; 16 Suppl 3():25-32. PubMed ID: 12740553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPARCL: the glimmer of statins for stroke risk reduction.
    Armani A; Toth PP
    Curr Atheroscler Rep; 2007 Nov; 9(5):347-51. PubMed ID: 18001616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study.
    Amarenco P; Bogousslavsky J; Callahan AS; Goldstein L; Hennerici M; Sillsen H; Welch MA; Zivin J;
    Cerebrovasc Dis; 2003; 16(4):389-95. PubMed ID: 14584489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Goldstein LB; Amarenco P; Zivin J; Messig M; Altafullah I; Callahan A; Hennerici M; MacLeod MJ; Sillesen H; Zweifler R; Michael K; Welch A;
    Stroke; 2009 Nov; 40(11):3526-31. PubMed ID: 19745172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.
    Byun YS; Yang X; Bao W; DeMicco D; Laskey R; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2017 Jan; 69(2):147-158. PubMed ID: 28081824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The need for increased utilization of statins after occlusive stroke.
    Hebert PR; Evans D; Schneider WR; Rodriquez-Paz E; Hennekens CH
    J Cardiovasc Pharmacol Ther; 2011; 16(3-4):364-7. PubMed ID: 21193682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin therapy and stroke prevention: what was known, what is new and what is next?
    Mazighi M; Lavallée PC; Labreuche J; Amarenco P
    Curr Opin Lipidol; 2007 Dec; 18(6):622-5. PubMed ID: 17993806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?
    Robins SJ
    Curr Opin Lipidol; 2003 Dec; 14(6):575-83. PubMed ID: 14624134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.